Stock Events

Stock Events

Aytu BioScience 

0
72
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29SepExpected
Q1 2026
Next
-0.45
-0.39
-0.32
-0.26
Expected EPS
-0.2550666
Actual EPS
N/A

Financials

-12.39%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
77.77MRevenue
-9.63MNet Income

Analyst Ratings

11.00Average Price Target
The highest estimate is 11.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AY21.MU. It's not an investment recommendation.
Microsoft
17
MSFT
Apple
15
AAPL
Alphabet
14
GOOGL
ExxonMobil
14
XOM

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is a global pharmaceutical company that competes with Aytu BioPharma in the development and marketing of medications in various therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson operates in the pharmaceutical sector, offering products that could directly compete with Aytu BioPharma's portfolio, especially in pediatrics and other health areas.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie competes in similar therapeutic areas as Aytu BioPharma, including testosterone replacement therapy and other pharmaceuticals.
Merck
MRK
Mkt Cap305.12B
Merck is a leading pharmaceutical company with a broad product line that can compete with Aytu BioPharma's offerings in various health conditions.
Lilly(Eli) &
LLY
Mkt Cap1.06T
Eli Lilly and Company is involved in the development and marketing of pharmaceutical products that could compete with Aytu BioPharma, especially in the areas of men's health.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.37B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing with Aytu BioPharma in various therapeutic areas.
Novartis
NVS
Mkt Cap293.94B
Novartis is a global healthcare company that offers products which could compete with Aytu BioPharma in several therapeutic areas, including pediatrics.
GSK
GSK
Mkt Cap105.71B
GlaxoSmithKline is a global healthcare company with a wide range of pharmaceutical products that could compete with Aytu BioPharma, especially in respiratory and pediatric medicines.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb is a global biopharmaceutical company with a diverse portfolio of products that could compete with Aytu BioPharma in various therapeutic areas.

About

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Show more...
CEO
Mr. Joshua R. Disbrow
Employees
164
Country
United States
ISIN
US0547547002

Listings

MU
DE
AY21.MU
STU
DE
AY21.STU
MU
DE
AY20.MU
XNAS
US
AYTU

0 Comments

Share your thoughts

FAQ

What is Aytu BioScience stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Aytu BioScience stocks are traded under the ticker AY21.MU.
When is the next Aytu BioScience earnings date?▼
Aytu BioScience is going to release the next earnings report on September 29, 2026.
What were Aytu BioScience earnings last quarter?▼
AY21.MU earnings for the last quarter are -0.45 EUR per share, whereas the estimation was -0.38 EUR resulting in a -19.55% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Aytu BioScience revenue for the last year?▼
Aytu BioScience revenue for the last year amounts to 77.77M EUR.
What is Aytu BioScience net income for the last year?▼
AY21.MU net income for the last year is -9.63M EUR.
How many employees does Aytu BioScience have?▼
As of July 28, 2026, the company has 164 employees.
In which sector is Aytu BioScience located?▼
Aytu BioScience operates in the Health & Wellness sector.
When did Aytu BioScience complete a stock split?▼
The last stock split for Aytu BioScience was on December 09, 2020 with a ratio of 1:10.
Where is Aytu BioScience headquartered?▼
Aytu BioScience is headquartered in Englewood, United States.